Abiraterone is a novel CYP17A1 inhibitor recently shown to extend the survival of men with castration resistant prostate cancer (CRPC). However, many men ultimately progress and mechanisms of resistance to abiraterone treatment in vivo have not been elucidated. We demonstrate in two xenograft models of CRPC that the clinical response to abiraterone is accompanied by marked suppression of tumor androgen levels, and identify increased expression of AR, ligand independent AR splice variants, and the steroidogenic transcriptome (including the CYP17A1 target gene) as potential mechanisms of adaptation to CYP17A1 blockade. These data suggest resistance can potentially be targeted by using higher dose levels of abiraterone or combinations with potent AR antagonists currently in development, and demonstrate that more effective suppression of AR signaling remains an important means of effectively treating advanced prostate cancer. Conclusions: These studies indicate that abiraterone reduces CRPC growth via suppression of intratumoral androgens and that resistance to abiraterone may occur through mechanisms that include upregulation of CYP17A1, and/or induction of AR and AR splice variants that confer ligand-independent AR transactivation.
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Conclusions: These studies indicate that abiraterone reduces CRPC growth via suppression of intratumoral androgens and that resistance to abiraterone may occur through mechanisms that include upregulation of CYP17A1, and/or induction of AR and AR splice variants that confer ligand-independent AR transactivation.
Research. 
INTRODUCTION
Prostate cancer develops resistance to serum androgen suppression in essentially all patients with advanced disease (1) . Upregulated androgen receptor (AR) expression and autonomous synthesis of androgens by neoplastic prostate epithelium (either de novo from cholesterol or through metabolism of adrenal precursors) are important contributors to castration resistant prostate cancer (CRPC) growth (2) (3) (4) (5) . Tissue androgens such as dihydrotestosterone (DHT) may be maintained via the "classical" pathway of steroidogenesis proceeding through dehydroepiandrosterone (DHEA), or through a "back-door" pathway using 5α-reduced steroid precursors as the primary source of DHT (6) . In addition to upregulated expression of full length AR (AR FL ), the generation of constitutively active AR variants by differential transcript splicing of the ligand binding domain has been described (2, (7) (8) (9) (10) (11) (12) . These AR splice variants have ligand independent activity, and AR v567es can also function by enhancing the response of AR FL to low ligand concentrations (10, 13) .
Abiraterone is a novel agent designed to suppress growth of CRPC by inhibiting CYP17A1, a rate limiting enzyme of steroidogenesis (14) . Potential sites of action include any organ capable of elaborating androgens, including testis, adrenal gland or prostate cancer tissue. Positive results in Phase I and II clinical trials, both before and after the use of docetaxel (15) (16) (17) , have led to phase III studies of abiraterone, demonstrating a survival advantage over prednisone alone in men with CRPC previously treated with docetaxel (18) .
Research.
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While clinical studies of abiraterone have demonstrated responses in the majority of men with CRPC, the extent of PSA declines and measureable tumor regression are variable, and the effect of abiraterone in suppressing tumor (as opposed to serum) androgens in men with CRPC has not been determined. As shown in multiple studies, suppression of serum androgens does not correlate well with suppression of tissue androgens in men undergoing androgen deprivation (4, 19, 20) . Moreover, most patients treated with abiraterone ultimately suffer tumor progression, and information delineating how resistance to abiraterone occurs is limited. Establishing the effect of abiraterone on tissue androgens and gene expression is critical for determining whether the clinical activity of abiraterone correlates with suppression of tissue androgens and for identifying potential mechanisms of resistance to abiraterone treatment.
To address these issues, we treated CRPC xenografts with abiraterone to determine the effects on tumor growth, tissue androgen concentrations, and tumor gene expression. Our results indicate that alterations in pathways of androgen metabolism and AR expression are mechanisms of molecular adaptation in response to abiraterone treatment, and consequently represent attractive targets for new therapeutic strategies.
METHODS
LuCaP Human Prostate Cancer Xenografts. The establishment and maintenance of the LuCaP23 and 35 xenografts from lymph node metastases of two individuals with CRPC as a component of the University of Washington Rapid Autopsy program has been previously described (21, 22) . The AR has been sequenced and codes for a wild-type protein in both xenografts. In eugonadal hosts, these lines produce serum PSA, regress in response to castration, and subsequently re-grow as castration-resistant (CR), PSAproducing variants that were utilized in the present studies. The CR variant of LuCaP35 has previously been termed LuCaP35V, but for consistency the CR variants of both Lu- Steroid measurements. Androgen levels were determined by mass spectrometry (MS) using methods we have recently described (24) . This procedure resulted in a lower limit of quantitation of 1 pg per sample for testosterone and DHT respectively. Intra-assay coefficients of variation generated using human serum for high, mid and low-range samples were 3.5, 3.1 and 3.8% for testosterone and 6.3, 4.3 and 15.8% for DHT, respectively.
RNA Isolation and Quantitative RT-PCR. RNA was isolated and prepared for quantitative PCR (qRT-PCR) as previously described (5) . cDNA was generated in a randomprimed reverse transcription reaction, and qRT-PCR reactions were performed in triplicate using an Applied Biosystems 7700 sequence detector with 5 ng of cDNA, 1 µM of each primer pair and SYBR Green PCR master mix (Applied Biosystems, Foster City, CA). Primers (Supp Data 1) were designed using the Web-based primer design service (25) and RODH4, DHRS9 (NT-3alpha HSD) and 17BHSD10 (26) for which previously published primer sequences were used. Specificity of amplification was assessed based on melting point of the dissociation curve. In certain cases, 2.5ul of amplified product (total reaction volume 10ul) was also run on a 2% agarose gel to assess for product size (compared to positive control) and the presence of extraneous bands (using a Hamamatsu digital camera with acquisition software from LabWorks).
Statistical Analysis. The effect of abiraterone on tumor growth was quantified using the following linear mixed effects model: 
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PSA levels were directly correlated in abiraterone-treated LuCaP35CR tumors (Pearson correlation r=0.8226; p=0.0006) but not in LuCaP23CR. These observations suggest that androgen-mediated effects on serum PSA levels may reflect alterations in release/secretion of PSA with or without associated changes in tumoral PSA transcription. 
Expression of Genes
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abiraterone treatment, is lower than that observed in clinical studies of CRPC tissues, in which CRPC metastases were compared to primary, untreated prostate tumors (5).
Expression of Genes Mediating Pre-receptor Regulation of DHT Levels. Tumor androgen levels reflect the sum total of activity in both androgen biosynthetic and androgen catabolic pathways. The back-conversion of 3α-diol to DHT, which can be mediated by enzymes with 3 alpha-hydroxysteroid reductase (3α-HSD) activity, has primarily been attributed to RL-HSD, although RODH4, RDH5, HSD17B10, and DHRS9 can also mediate this reaction and are expressed to varying degrees in prostate tissue (29, 30) . We therefore examined whether genes involved in pre-receptor regulation of DHT levels via back-conversion of 3-α-androstanediol (3-α-diol) to DHT were also altered by abiraterone treatment. Interestingly, changes in expression of oxidative genes mediating backconversion of 3α-diol to DHT in abiraterone treated tumors were mixed, with increases in genes such as DHRS9 in LuCaP23CR, and RDH5 in LuCaP35, but significant decreases in expression of RL-HSD in both LuCaP23CR and LuCaP35CR ( Table 1) .
The marked suppression of RL-HSD in response to ligand inhibition with abiraterone is consistent with a recent report demonstrating suppression of RL-HSD levels in CWR22 PCa xenografts in response to castration (30) , and may explain the relatively low levels of androgens measured in abiraterone-treated tumors despite general induction of genes mediating androgen biosynthesis. Notably, tumor DHT levels were strongly corre- (13, (34) (35) (36) . Studies to delineate whether sequential or concurrent use of these agents with abiraterone can improve tumor growth inhibition and/or suppress adaptation in xenograft models will be important to provide rationale for human studies evaluating these agents in the treatment of clinical disease.
The response to abiraterone in our study is most likely due to suppression of de novo intratumoral steroidogenesis (due to the reported lack of CYP17A1 in rodent adrenal glands) (37, 38), whereas in human studies the response to abiraterone may reflect inhibition of both adrenal and/or intratumoral CYP17A1 activity. Importantly, the proposed mechanism driving clinical activity of abiraterone in both scenarios is a decrease in intratumoral androgens (whether from suppression of adrenal steroidogenesis, intratumoral steroidogenesis, or both). Our observations confirm this expected mechanism of activity. 
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variants following abiraterone treatment are likely to be clinically relevant mechanisms of resistance regardless of whether tumoral CYP17A1 activity is present.
Another consideration for translation of our results to the clinical setting is that men with CRPC are likely to be treated with abiraterone plus prednisone (or dexamethasone) rather than abiraterone alone. In castrate men treated with abiraterone, glucocorticoids are primarily used to inhibit pituitary-mediated secretion of ACTH (induced by adrenal CYP17A1 inhibition) which can exacerbate side effects of mineralocorticoid excess, but may potentially inhibit tumor growth directly (39) . ACTH may also drive clinically significant increases in production of androgenic precursors by the adrenal gland, as evidenced by PSA declines following the addition of dexamethasone in men who had progressed on abiraterone (15) . Thus, the inclusion of prednisone in men with CRPC is likely to accentuate any decrease in tumor androgens caused by abiraterone, and may accentuate the types of tumoral responses observed in the abiraterone-treated xenografts.
Our hypothesis that tumoral androgens in these xenograft studies are derived from de-novo steroidogenesis is consistent with previous observation that a subset of CRPC metastases have increased levels of transcripts for CYP17A1 and HSD3B1 (necessary for de novo synthesis) and the demonstration by Locke et al that CRPC xenografts are capable of synthesizing DHT from acetate (5, 6, 40) . However, alternative androgenic precursors (of adrenal or other origin) may also be present in the circulation as potential substrates. Unfortunately, serum samples adequate to assess circulating androgen levels were 
22 not available for analysis in this study. In addition, the duration of abiraterone treatment in our study was 21 days. It is possible that more prolonged treatment would have resulted in a more robust induction of the adaptive changes already observed. Finally, metastatic CRPC is characterized by significant heterogeneity, while our conclusions reflect an analysis of only two CRPC phenotypes, and we had small numbers in some of the treatment groups. These limitations can be addressed by evaluating diverse panels of CRPC xenografts over a more prolonged time-course of therapy, and through studies of human tumor biopsies obtained at abiraterone resistance.
In conclusion, our finding that abiraterone suppresses intratumoral androgens and inhibits CRPC growth supports the hypothesis that tissue androgen levels are major contributors to AR signaling and mediators of CRPC progression. Though hypothesized, this is the first demonstration that the efficacy of abiraterone is related to its ability to suppress tumor androgen levels and complements previously published data from phase I studies regarding suppression of serum androgens (15, 41) . Our results also identify potential mechanisms of adaptation to CYP17A1 blockade, including increased expression of AR, AR splice variants, and the steroidogenic transcriptome. Importantly, these adaptive mechanisms can potentially be targeted by using higher dose levels of abiraterone or combinations with potent AR antagonists currently in development. These data provide optimism that more effective suppression of AR signaling will continue to be an important means of effectively treating advanced prostate cancer. ) between controls and abiraterone-treated tumors in the indicated groups (Early, Resistant or Treated). Fold changes for genes which were not statistically significant are omitted **P values from two sample t-tests. P values < 0.05 were considered significant. Genes with p values <0.10 were considered trending toward significance if fold change was also > 1.5 (shown in italics) .
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